Literature DB >> 2425957

Incorporation of 5-fluorodeoxycytidine and metabolites into nucleic acids of human MCF-7 breast carcinoma cells.

J Kaysen, D Spriggs, D Kufe.   

Abstract

Several mechanisms of action have been proposed for the antitumor agents, 5-fluorouracil (FUra) and 5-fluorodeoxyuridine (FdUrd), including their incorporation into both cellular RNA and DNA. Another fluorinated pyrimidine, 5-fluorodeoxycytidine (FdCyd), has been shown to be even more active than FdUrd against certain experimental tumors. Although FdCyd is deaminated to FdUrd, the precise mechanism of action of this agent has remained unclear. We have therefore monitored the incorporation of FdCyd and its metabolites into the nucleic acids of human MCF-7 breast carcinoma cells. The results demonstrate the internucleotide incorporation of FdCyd in MCF-7 DNA. The results also demonstrate that FUra residues are detectable in both MCF-7 DNA and RNA following treatment with FdCyd. Cytidine and deoxycytidylate deaminase inhibitors increased the extent of (FdCyd) DNA synthesis, but they had little if any effect on formation of (FUra) RNA. In contrast, deoxyuridine increased incorporation of FdCyd into DNA and blocked the formation of FUra RNA. Deoxyuridine also enhanced the cytotoxicity associated with FdCyd treatment. The present results further demonstrate that FdCyd inhibits postsynthetic methylation of MCF-7 DNA. These findings would suggest that FdCyd has multiple mechanisms of action and that incorporation of this agent into DNA distinguishes its effects from those of FUra and FdUrd.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2425957

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

Review 1.  DNA methylation: its role in cancer development and therapy.

Authors:  Carla Kurkjian; Shivaani Kummar; Anthony J Murgo
Journal:  Curr Probl Cancer       Date:  2008 Sep-Oct       Impact factor: 3.187

2.  Elevation of plasma levels of fluorinated pyrimidines by guanosine 5'-monophosphate.

Authors:  M Iigo; Z Yamaizumi; S Nishimura; A Hoshi
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

3.  A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine, administered with tetrahydrouridine.

Authors:  Edward M Newman; Robert J Morgan; Shivaani Kummar; Jan H Beumer; M Suzette Blanchard; Christopher Ruel; Anthony B El-Khoueiry; Mary I Carroll; Jessie M Hou; Chun Li; Heinz J Lenz; Julie L Eiseman; James H Doroshow
Journal:  Cancer Chemother Pharmacol       Date:  2015-01-08       Impact factor: 3.333

4.  Enzymatic methylation of DNA in cultured human cells studied by stable isotope incorporation and mass spectrometry.

Authors:  Jason L Herring; Daniel K Rogstad; Lawrence C Sowers
Journal:  Chem Res Toxicol       Date:  2009-06       Impact factor: 3.739

5.  Oral and intravenous pharmacokinetics of 5-fluoro-2'-deoxycytidine and THU in cynomolgus monkeys and humans.

Authors:  Julianne L Holleran; Jan H Beumer; David L McCormick; William D Johnson; Edward M Newman; James H Doroshow; Shivaani Kummar; Joseph M Covey; Myrtle Davis; Julie L Eiseman
Journal:  Cancer Chemother Pharmacol       Date:  2015-09-01       Impact factor: 3.333

6.  Caffeic Acid, Quercetin and 5-Fluorocytidine-Functionalized Au-Fe3O4 Nanoheterodimers for X-ray-Triggered Drug Delivery in Breast Tumor Spheroids.

Authors:  Stefanie Klein; Luitpold V R Distel; Winfried Neuhuber; Carola Kryschi
Journal:  Nanomaterials (Basel)       Date:  2021-04-29       Impact factor: 5.076

Review 7.  5-Aza-4'-thio-2'-deoxycytidine, a New Orally Bioavailable Nontoxic "Best-in-Class": DNA Methyltransferase 1-Depleting Agent in Clinical Development.

Authors:  William B Parker; Jaideep V Thottassery
Journal:  J Pharmacol Exp Ther       Date:  2021-09-09       Impact factor: 4.402

8.  Robust Classification of Small-Molecule Mechanism of Action Using a Minimalist High-Content Microscopy Screen and Multidimensional Phenotypic Trajectory Analysis.

Authors:  Nathaniel R Twarog; Jonathan A Low; Duane G Currier; Greg Miller; Taosheng Chen; Anang A Shelat
Journal:  PLoS One       Date:  2016-02-17       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.